StockpollyBeta
Get App
Popularity #1,726
ARDX · NASDAQ · Biotechnology

Ardelyx (ARDX)

Commercializes IBSRELA and XPHOZAH from a gut-local NHE3 inhibition platform.

$3.59
After-hours close−0.04 (−1.21%)
At close$3.63(+3.71%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue5634467398116749811012594121
Cost of revenue858101618131351256
Gross profit492938638398618510511390115
4157637780909899101108122128
Research & development91010121514141517222026
Selling, general & administrative33485365657683848486102101
Operating income7−28−25−1428−36−1455−33−12
−10−2−3−3−3−4−5−6−5−5−4
Interest expense234556678875
Other non-operating income−1−2−2−2−2−2−2−2−2−2−2−1
Income before tax7−28−26−16−15−40−19−10−38−17
Income tax expense000000100000
Net income from continuing operations7−29−27−16−15−41−19−10−38−17
Net income7−29−27−16−15−41−19−10−38−17
EPS, basic$0.03−$0.12−$0.11−$0.07−$0.00$0.02−$0.17−$0.08−$0.00−$0.00−$0.15−$0.07
EPS, diluted$0.03−$0.12−$0.11−$0.07−$0.00$0.02−$0.17−$0.08−$0.00−$0.00−$0.15−$0.07
Weighted average shares, basic223232233235236237239240242244246248
Weighted average shares, diluted228232233235236244239240242244246248
EBITDA9−25−22−11511−33−1288−30−10
Depreciation & amortization000111111112
EBIT9−26−22−11511−34−1377−31−12